Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2.25% is 97% above its 5-year average of -66.29%, near the high end of its 5-year range (-1890.30%–20.71%).
126.39% below its 12-month average of 8.53%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.71%.
EBITDA MARGIN
-2.25%
EBITDA MARGIN AVG TTM
8.53%
EBITDA MARGIN AVG 3Y
-34.40%
EBITDA MARGIN AVG 5Y
-66.29%
EBITDA MARGIN AVG 10Y
-161.26%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-126.39%
CURRENT VS 3Y AVG
+93.46%
CURRENT VS 5Y AVG
+96.61%
CURRENT VS 10Y AVG
+98.60%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cronos Group Inc.
Market Cap
$1.21B
EBITDA Margin
-2.25%
TTM Avg
8.53%
3Y Avg
-34.40%
5Y Avg
-66.29%
Market Cap
$1.20B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.16B
EBITDA Margin
21.67%
TTM Avg
19.38%
3Y Avg
14.20%
5Y Avg
2.75%
Market Cap
$1.14B
EBITDA Margin
21.12%
TTM Avg
16.04%
3Y Avg
11.58%
5Y Avg
9.26%
Market Cap
$1.14B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
EBITDA Margin
-0.59%
TTM Avg
3.42%
3Y Avg
-15.99%
5Y Avg
-18.77%
Market Cap
$1.12B
EBITDA Margin
28.28%
TTM Avg
32.08%
3Y Avg
32.10%
5Y Avg
26.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.21B | -2.25% | 8.53% | -34.40% | -66.29% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 21.67% | 19.38% | 14.20% | 2.75% |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 21.12% | 16.04% | 11.58% | 9.26% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | -0.59% | 3.42% | -15.99% | -18.77% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 28.28% | 32.08% | 32.10% | 26.80% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | N/A | N/A | N/A | N/A |
Gross Margin
36.2%
EBITDA Margin
-2.3%
Operating Margin
-12.0%
Net Margin
31.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 20.71% |
| 2026-03-31 | 5.03% |
| 2025-12-31 | 11.91% |
| 2025-09-30 | 8.34% |
| 2025-06-30 | -3.35% |
| 2025-03-31 | -3.82% |
| 2024-12-31 | -30.78% |
| 2024-09-30 | -87.81% |
| 2024-06-30 | -50.60% |
| 2024-03-31 | -56.22% |
| 2023-12-31 | -85.55% |
| 2023-09-30 | -79.11% |
| 2023-06-30 | -95.89% |
| 2023-03-31 | -94.20% |
| 2022-12-31 | -118.52% |
| 2022-09-30 | -117.04% |
| 2022-06-30 | -97.56% |
| 2022-03-31 | -127.44% |
| 2021-12-31 | -603.30% |
| 2021-09-30 | -257.69% |
| 2021-06-30 | -1890.30% |
| 2021-03-31 | -329.70% |
| 2020-12-31 | -331.22% |
| 2020-09-30 | -342.96% |
| 2020-06-30 | -738.55% |
| 2020-03-31 | -520.61% |
| 2019-12-31 | -800.09% |
| 2019-09-30 | -376.16% |
| 2019-06-30 | -211.06% |
| 2019-03-31 | -323.93% |
| 2018-12-31 | -208.28% |
| 2018-09-30 | -119.53% |
| 2018-06-30 | 25.33% |
| 2018-03-31 | -46.83% |
| 2017-12-31 | 31.65% |
| 2017-09-30 | 13.21% |
| 2017-06-30 | -206.90% |
| 2017-03-31 | -104.14% |
| 2016-12-31 | 227.69% |
| 2016-09-30 | -358.62% |
| 2016-06-30 | 133.05% |
| 2016-03-31 | 2716.80% |
| 2015-12-31 | 59.35% |
| 2015-09-30 | 621.47% |
| 2015-06-30 | 600.78% |
| 2015-03-31 | 405.45% |
| 2014-12-31 | 461.84% |
| 2014-09-30 | 27.21% |
| 2014-06-30 | -3186.30% |
| 2014-03-31 | -0.17% |
| 2013-12-31 | -0.19% |
| 2013-09-30 | 0.00% |
